Brief: Scynexis reports Preclinical Data On Second Generation Fungerp SCY-247
24/10/2023 14:05
Oct 24 (Reuters) - SCYNEXIS Inc SCYX.O :
* SCYNEXIS PRESENTS NEW PRECLINICAL DATA ON SECOND
GENERATION
FUNGERP SCY-247 AT THE 11TH CONGRESS ON TRENDS IN MEDICAL
MYCOLOGY (TIMM)
Source text for Eikon: ID:nGNX5NfYPp
Further company coverage: SCYX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview